20/20 Biolabs, Inc. income statement

In fiscal 2025, 20/20 Biolabs, Inc. reported revenue of $2.0m, up 16.7% on the year before, operating income of −$3.3m (a -162.9% margin) and net income of −$3.7m, or −$0.76 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

20/20 Biolabs, Inc.: income statement, annual
Fiscal year	2024Dec 2024	2025Dec 2025
Revenue	1,752	2,045
Cost of revenue	1,392	1,441
Gross profit	360	605
Research and development	1,262	593
Selling, general and administrative	4,760	3,343
Operating income	−5,677	−3,331
Interest expense	13	156
Net income	−5,552	−3,739
Diluted EPS	−$1.16	−$0.76
Diluted shares (average)	5m	5m
EBITDA	−5,561	−3,268

US$ thousands unless shown otherwise. Fiscal quarters.

20/20 Biolabs, Inc.: income statement, quarterly
Quarter	2025 Q1Mar 2025	2025 Q2Jun 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	554	535	353	731
Cost of revenue	388	372	290	426
Gross profit	166	163	63	305
Research and development	137	194	153	258
Selling, general and administrative	801	815	1,353	1,291
Operating income	−772	−846	−1,443	−1,244
Interest expense	1	1	267	272
Net income	−765	−841	−2,175	−1,506
Diluted EPS	−$0.16	−$0.17	−$0.28	−$0.26
EBITDA	−754	−831	−1,431	−1,233

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from 20/20 Biolabs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 20/20 Biolabs, Inc.